European Psychiatry - Volume 41 - April 2017

16 / 916

S12 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S8–S52
care providers were required to ponder over ethical dilemmas or
decisions. Several challenges were reported, such as: taking into
account and articulating personal freedom or needs with collec-
tive functioning or organizational constraints before, during and
after the assisted suicide; reconciliating self-determination with
protection towards vulnerable people (beneficere, nonmaleficere).
Conclusions Assisted suicide challenges and changes professional
end-of-life practices. Education and support should be provided to
health and social care providers faced with it.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Symposium: Is it possible to prevent Alzheimer’s
disease?
S014
Setting the scene: The evidence for
pre-clinical change, projections of the
impact of intervention, and
implications for public health
T.C. Russ ∗, K. Ritchie , G.M. Terrera , C.W. Ritchie
1 Centre for Dementia Prevention, University of Edinburgh,
Edinburgh, United Kingdom
2 Inserm, Montpellier, France
3 Department of Psychology, University of Victoria, Canada
Alzheimer’s disease has long been considered a neurodegenerative
disorder of late life for which there is currently no disease-
modifying treatment. This view is now being revised as increasing
evidence suggests a long pre-clinical phase extending back into
mid-life during which there is exposure to multiple potentially
reversible risk factors. Further thought is now being given to the
possibility of both early life intervention programs and devel-
opment of new drug treatments focusing on the pre-dementia
period. But how can the impact of such treatments be measured
at this early stage since overt dementia may not be diagnosed
for decades? In the four talks in this symposium, we will dis-
cuss evidence for pre-clinical change, theoretical models which
have been used to project the possible impact of risk factor mod-
ification in mid-life and their integration into a future public
health strategies. The development of new statistical risk mod-
els to determine the impact of such prevention measures will be
outlined. We will consider the possibilities for drug development
targeting the pre-clinical period before presenting the PREVENT
Project and EPAD ), a multi-million euro IMI-
Horizon 2020 funded project for the development of pre-clinical
proof of concept trials. Titles of the four presentations: 1. Setting
the scene: the evidence for pre-clinical change, projections of the
impact of intervention, and implications for public health (TCR) 2.
New statistical risk models for determining the impact of preven-
tion measures in the pre-dementia period (GMT) 3. The PREVENT
Study: a prospective cohort study to identify mid-life biomarkers
of late-onset Alzheimer’s disease (KR) 4. The European Prevention
of Alzheimer’s Dementia (EPAD) Project: developing interven-
tions for the secondary prevention of Alzheimer’s dementia
(CWR)
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Symposium: Upscaling mental healthcare -
Implementing guidance and mental health care
recommendations in Europe
S015
How can guidance recommendations
contribute to better mental health?
W. Gaebel
Heinrich-Heine-Universität, Düsseldorf, Germany
Introduction In European countries, the quality of mental health-
care services is often limited due to scarce and inequitable
distributed resources, and inefficient use of existing resources.
Against this background, the EPA Guidance provides recommen-
dations on how to optimize quality of mental healthcare for all
European countries.
Objectives Provision of guidance recommendations in order to
support optimization and harmonization of mental healthcare ser-
vices in European countries.
Methods By means of evidence and consensus-based methods
EPA guidance papers are developed by experts in psychiatry and
related fields
Results As of 2012, five EPA guidance series have been developed
and published hey focus on various aspects of mental health-
care and clinical situations that have not been covered by medical
guidelines yet but are considered important to deliver high quality
mental healthcare. Papers deal amongst others with topics relating
to quality assurance of mental health services, as quality of men-
tal health service structures and processes, and building trust in
mental health services.
Conclusions EPA guidance recommendations can improve men-
tal healthcare provision and thereby contribute to better mental
health of persons receivingmental healthcare. For this purpose, rec-
ommendations need to be widely disseminated and implemented
in European countries.
Disclosure of interest Unterstützung bei Symposien/Symposia
Support
− Janssen-Cilag GmbH, Neuss
− Aristo Pharma GmbH, Berlin
− Lilly Deutschland GmbH, Bad Homburg
− Servier Deutschland GmbH, München− Fakultätsmit-
glied/Faculty Member
− Lundbeck International Neuroscience Foundation (LINF), Däne-
mark
References
[1] Gaebel W, Becker T, Janssen B, Munk-Jorgensen P, Musalek M,
Rössler W, Sommerlad K, Tansella M, Thornicroft G, Zielasek
J. EPA guidance on the quality of mental health services. Eur
Psychiatry 2012;27:87–113.
[2] Gaebel W, Möller H-J. European Guidance - a project of
the European Psychiatric Association. European Psychiatry
2012;27:65–7.
S016
Implementation of EPA guidance -
One way for all countries?
M.M. Carrasco
Instituto de Investigaciones Psiquiátricas, Spain
The European Psychiatric Association (EPA) guidance project
launched in 2008 has the aim of providing European psychiatry
with guidance in topics, which are relevant for European mental
health care. Guidance from a European perspective can be favor-
able against the background of a growing sense of Europe and
the desirable associated harmonization on all levels of health care
policy.